BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
BridgeBio received marketing authorization from Brazil's ANVISA for acoramidis, branded as BEYONTTRA, to treat wild-type or variant transthyretin amyloidosis cardiomyopathy (ATTR-CM). The approval is based on the Phase 3 ATTRibute-CM study, which demonstrated a 42% reduction in the composite of all-cause mortality and recurrent cardiovascular hospitalization compared to placebo at 30 months.
Key figures
- Drug Name
- BEYONTTRA (acoramidis)
- Phase Of Trial
- Phase 3
- Acm cvh reduction
- 42%
- Study participants
- 632
- Cvh events reduction
- 50%
- Study duration months
- 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.